Takeda
Calithera Biosciences Acquires Takeda Cancer Drugs in $45M Deal
The company will begin Phase II trials of sapanisertib in NSCLC and mivavotinib in diffuse large B-cell lymphoma in 2022.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines
The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers
FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor
The agency approved Foundation Medicine's tissue-based, next-generation sequencing test to identify patients with ALK-positive NSCLC eligible for Alunbrig.
FDA Accepts Takeda's NDA for EGFR Exon20 Insertion-Mutated NSCLC Treatment
The agency granted priority review to Takeda's mobocertinib application seeking approval in metastatic non-small cell lung cancer patients with certain EGFR mutations.